< Arab Finance - News - Rameda acquires anticoagulant drug
Count Down to relaunch

Rameda acquires anticoagulant drug

Rameda acquires anticoagulant drug

Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) has concluded the acquisition of an anticoagulant drug, according to a press release to the Egyptian Exchange (EGX) on May 23rd.

The deal comes within the framework of Rameda’s growth strategy aiming at boosting its portfolio of medicines through acquiring promising medicine products.

The new acquisition is sought to support the company’s growth as the anticoagulant drug recorded a compound annual growth rate (CAGR) of 87% in the market during the period from 2018 until 2021, according to IQVIA.

The company is expected to generate annual revenue of around EGP 30 million from the newly acquired drug.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.

It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

#Related keywords

Recommended Stocks

13 Jun 2022
Delta Sugar SUGR

All rights reserved to Arab Finance 2020 ©

Back to top